Endo Pharmaceuticals Holdings News

Bioniche Life Sciences Inc. shares soared Friday after it announced a multi-million-dollar deal to sell the exclusive right to develop and market its bladder cancer drug in the United States to Endo Pharmaceuticals Inc.

It is one of the world's most popular drugs, considered safe to treat fevers in children and aches and pains in pregnant women.

Two major shareholders who oppose Danbury-based Penwest Pharmaceuticals Co.'s plan to develop a new drug now sit on its board of directors.

Teva Pharmaceutical Industries Ltd., which bought Barr Laboratories Inc. for $7.4 billion last year, is ready for another "major" acquisition and may look beyond generic drugs for the purchase, Chief Executive Officer Shlomo Yanai said.

BUYINS.NET, www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for June 17, 2009.

NOIDA, India An India-based pharmaceutical company has announced it has entered a discovery and development collaboration with a United States-based pharmaceutical company.

Penwest Pharmaceuticals Co., Endo Pharmaceuticals and Valeant Pharmaceuticals have announced that Endo has signed an exclusive license with Valeant allowing it to market OPANA ER in Canada, Australia and New Zealand.

Endo Pharmaceuticals Holdings Inc - Detailed Product Pipeline - companiesandmarkets.com adds new report © companiesandmarkets.com companiesandmarkets.com 2009-05-29 15:23:01 - Endo Pharmaceuticals Holdings Inc - Detailed Product Pipeline - a new market research report on companiesandmarkets.com ...

Based on the aggregated intelligence of 130,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, drug developer Endo Pharmaceuticals Holdings has earned a coveted five-star ranking .

Logical Therapeutics, Inc , a biotechnology company focused on the development of products that treat diseases associated with inflammation, today announced that Peter A. Lankau has been appointed Chief Executive Officer, and has been elected to the Company's Board of Directors.

CHADDS FORD, Pa., May 7 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals announced today the appointment of Alan G. Levin as the company's executive vice president and chief financial officer, effective June 1, 2009.

May 06, 2009 By Jeanie Casison Harith Productions puts on a show-stopping incentive travel program for Endo Pharmaceuticals in Rio de Janeiro.

On Campus Submitted by Christopher Michalski on 2009-05-04.   Central Connecticut State University will hold commencement exercises for undergraduate candidates on Saturday, May 23, at 10:30 am in the XL Center in Hartford.

Note that strong international growth offset somewhat weak domestic results, which likely indicate increasing competition.

Excluding costs related to its acquisition of Indevus earlier this year, Endo reported earnings of $79 million, or 67 cents a share, compared with the year-ago period's $68.2 million, or 51 cents a share.

Pennyperformers.com "Penny Stocks that Perform" picks are: AVI BioPharma, Inc. , Endo Pharmaceuticals , O.C. BEVERAGES, INC.

Long-term Data Presented at AUA Annual Meeting CHICAGO, April 28 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals today released new long-term clinical trial data in men with hypogonadism who were treated for 21 months with testosterone undecanoate -- 750 mg) injection, a long-acting testosterone replacement therapy in development in the U.S. for ...

Endo Pharmaceuticals Holdings Inc. - Financial and Strategic Analysis Review - companiesandmarkets.com adds new report 2009-04-23 13:17:01 - Endo Pharmaceuticals Holdings Inc.

Endo Pharmaceuticals announced today the appointment of Nancy J. Hutson, Ph.D., to the company's board of directors.

The Visiting Nurse Associations of America , the National Pain Foundation and the National Council on Aging today announced the re-launch of AfterShingles.com, an online resource offering tools and information to help educate consumers about shingles and postherpetic neuralgia , or after-shingles pain, its impact on people's lives and steps to take ...